Advice
Following an abbreviated submission
aripiprazole intramuscular injection (Abilify) is accepted for use in NHS Scotland for the rapid control of agitation and disturbed behaviours in patients with schizophrenia when oral therapy is not appropriate.
Where aripiprazole is an appropriate antipsychotic, this new formulation provides rapid control of symptoms at an equivalent cost to solid oral dosage forms.
SMC has not recommended aripiprazole for use within NHS Scotland for the treatment of manic episodes in bipolar 1 disorder. Therefore this formulation is not recommended for the rapid control of agitation and disturbed behaviours in patients with manic episodes in bipolar 1 disorder.
Download detailed advice51KB (PDF)
Medicine details
- Medicine name:
- aripiprazole IM (Abilify)
- SMC ID:
- 522/08
- Indication:
- For the rapid control of agitation and disturbed behaviours in patients with schizophrenia, when oral therapy is not appropriate
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 December 2008